Mind Medicine, Inc. (MindMed) plans to take MM120 (lysergide D-tartrate), a proprietary low-dose formulation of the psychedelic drug LSD, into Phase III clinical trials in generalized anxiety disorder (GAD) during the second half of 2024 based on continued positive data readouts from a Phase IIb trial, including a 7 March update that showed a single dose of the drug effectively treated GAD for up to 12 weeks after administration.
MindMed Ready To Take LSD Therapy Into Phase III For Anxiety
Treatment Infrastructure In Place Due To J&J’s Spravato
Mind Medicine’s LSD product MM120 will move into Phase III in the second half of 2024 after it showed efficacy in generalized anxiety disorder out to 12 weeks with a single administration in Phase IIb.
More from Clinical Trials
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
More from R&D
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.